DP Chin, D Osmond, K Page-Shafer, J Glassroth, MJ Rosen, LB Reichman, PA Kvale, JM Wallace, WK Poole and PC Hopewell
University of California, San Francisco, California, USA.

Testing with antigens that elicit delayed-type cutaneous hypersensitivity reactions is commonly used to evaluate immune competence in persons infected with the human immunodeficiency virus; however, the reliability of such testing has not been determined. We performed serial testing with tuberculin, mumps, and Candida antigens in 491 HIV-infected persons and found that 30% of persons who initially had no reaction (0 mm) to any of the three antigens, and, thus, were considered to be anergic, had reaction to the mumps or Candida antigen when they were retested 12 months later. We also examined the results of mumps antigen tests in 50 subjects who had a negative tuberculin tests after an initial positive test. The mumps antigen test was positive in 39% of the subjects when the tuberculin test was falsely negative. We conclude that tests commonly used to define anergy cannot reliably identify the anergic state. Moreover, using the mumps antigen to aid in the interpretation of the tuberculin test will often lead to erroneous conclusions. These data indicate that the results of anergy testing should not be used to make individual patient decisions concerning preventive therapy for tuberculosis.

This article has been cited by other articles:

				M. STEIN, B. SELA-RAZON, Y. KLETER, and E. SOMEKH Reliability of Control Skin Tests with Common Antigens in Children Undergoing Tuberculin Skin Test Ann. N.Y. Acad. Sci., August 1, 2007; 1109(1): 235 - 239. [Abstract] [Full Text] [PDF]

				E. C. JONES-LOPEZ, A. OKWERA, H. MAYANJA-KIZZA, J. J. ELLNER, R. D. MUGERWA, C. C. WHALEN, and THE UGANDA-CASE WESTERN RESERVE UNIVERSITY RESEARC DELAYED-TYPE HYPERSENSITIVITY SKIN TEST REACTIVITY AND SURVIVAL IN HIV-INFECTED PATIENTS IN UGANDA: SHOULD ANERGY BE A CRITERION TO START ANTIRETROVIRAL THERAPY IN LOW-INCOME COUNTRIES? Am J Trop Med Hyg, January 1, 2006; 74(1): 154 - 161. [Abstract] [Full Text] [PDF]

				Pediatric Tuberculosis Collaborative Group Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents Pediatrics, October 1, 2004; 114(4/S2): 1175 - 1201. [Abstract] [Full Text] [PDF]

				P. Cahn, H. Perez, G. Ben, and C. Ochoa Tuberculosis and HIV: A Partnership Against the Most Vulnerable J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2003; 2(3): 106 - 123. [Abstract] [PDF]

				R. M. Jasmer, P. Nahid, and P. C. Hopewell Latent Tuberculosis Infection N. Engl. J. Med., December 5, 2002; 347(23): 1860 - 1866. [Full Text] [PDF]

				K. J. Swartzman Latent tuberculosis treatment Can. Med. Assoc. J., September 1, 2002; 167(5): 453 - 454. [Full Text]

				J. C. Delgado, E. Y. Tsai, S. Thim, A. Baena, V. A. Boussiotis, J.-M. Reynes, S. Sath, P. Grosjean, E. J. Yunis, and A. E. Goldfeld Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia PNAS, May 28, 2002; 99(11): 7576 - 7581. [Abstract] [Full Text] [PDF]

				P. M. Small and P. I. Fujiwara Management of Tuberculosis in the United States N. Engl. J. Med., July 19, 2001; 345(3): 189 - 200. [Full Text] [PDF]

				Diagnostic Standards and Classification of Tuberculosis in Adults and Children . This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement was endorsed by the Council of the Infectious Disease Society of America, September 1999 Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1376 - 1395. [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				A. M. Mandalakas, L. Guay, P. Musoke, C. Carroll-Pankhurst, and K. N. Olness Human Immunodeficiency Virus Status and Delayed-Type Hypersensitivity Skin Testing in Ugandan Children Pediatrics, February 1, 1999; 103(2): 21e - 21. [Abstract] [Full Text]

				J. L. JOHNSON, S. NYOLE, A. OKWERA, C. C. WHALEN, P. NSUBUGA, V. PEKOVIC, R. HUEBNER, R. S. WALLIS, P. N. MUGYENYI, R. D. MUGERWA, et al. Instability of Tuberculin and Candida Skin Test Reactivity in HIV-infected Ugandans Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1790 - 1796. [Abstract] [Full Text] [PDF]

				H. Sawert, E. Girardi, G. Antonucci, M. C. Raviglione, P. Viale, G. Ippolito, and for the Gruppo Italiano di Studio Tubercolosi e AI Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count Arch Intern Med, October 26, 1998; 158(19): 2112 - 2121. [Abstract] [Full Text] [PDF]

				T. Lincoln, V. Lynch, and T. J. Conklin Skin Anergy Testing and Tuberculosis Surveillance Journal of Correctional Health Care, October 1, 1997; 4(2): 139 - 153. [Abstract] [PDF]

				F. M. Gordin, J. P. Matts, C. Miller, L. S. Brown, R. Hafner, S. L. John, M. Klein, A. Vaughn, C. L. Besch, G. Perez, et al. A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for Tuberculosis N. Engl. J. Med., July 31, 1997; 337(5): 315 - 320. [Abstract] [Full Text] [PDF]

				C. L. DALEY, J. A. HAHN, A. R. MOSS, P. C. HOPEWELL, and G. F. SCHECTER Incidence of Tuberculosis in Injection Drug Users in San Francisco . Impact of Anergy Am. J. Respir. Crit. Care Med., January 1, 1997; 157(1): 19 - 22. [Abstract] [Full Text]

				Unreliable Anergy Tests AIDS Clinical Care, September 1, 1996; 1996(901): 13 - 13. [Full Text]

				HOW RELIABLE IS ANERGY TESTING IN HIV-POSITIVE PATIENTS? Journal Watch (General), July 12, 1996; 1996(712): 5 - 5. [Full Text]